Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to improve patient access to cancer and complex disease treatments.
The problem
Patients may face barriers accessing certain cancer and complex therapies due to insurance coverage decisions, prior authorization requirements, or other regulatory obstacles.
The proposal
The bill modifies healthcare regulations to expand patient access to cancer treatments and complex therapies, likely through changes to insurance requirements or FDA approval processes.
The impact
Cancer patients, insurance companies, pharmaceutical companies, and healthcare providers would be affected by changes to treatment access and coverage requirements.
Patients with cancer and complex diseases could access newer treatments more quickly. This reduces waiting times that might otherwise delay life-saving care. Faster access can improve health outcomes for serious conditions.
The bill may reduce prior authorization requirements that delay treatment decisions. Fewer bureaucratic steps means doctors and patients can act faster on medical recommendations.
Expanding access gives patients more options in choosing their treatment. This respects patient autonomy and allows doctors to recommend best treatments without insurance restrictions.
Complex therapies often treat rare conditions with few treatment options. This bill could help patients with these conditions access specialized treatments.
Expanding access to expensive cancer drugs and complex therapies may increase overall healthcare spending. Insurance premiums could rise for everyone, affecting affordability. Costs may shift to patients or taxpayers.
Reducing insurance oversight might limit checks on whether treatments are safe and effective. Some treatments might be used before sufficient evidence exists about their safety.
Insurers facing stricter requirements might increase prices significantly or leave certain markets. This could reduce competition and increase costs for all patients.
Even with expanded coverage rules, wealthier patients may access treatments first. Those without good insurance might still face barriers despite the new law.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.